trending Market Intelligence /marketintelligence/en/news-insights/trending/y886ew6l8xd8v9_lprkkqa2 content esgSubNav
In This List

AzurRx BioPharma appoints chief medical officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


AzurRx BioPharma appoints chief medical officer

AzurRx BioPharma Inc. appointed James Pennington to the position of chief medical officer.

Pennington's appointment comes as the biotechnology company prepares to initiate a phase 2 clinical study of its drug MS1819 in cystic fibrosis and file an investigational drug application for the therapy in the U.S.

Pennington served as vice president at Bayer Corp., a unit of Bayer AG.

New York-based AzurRx BioPharma develops therapies to treat gastrointestinal diseases and infectious diseases.